Can I read Imatinib: Grade 3 maculopapular lesions and exfoliative reaction: case report on EtoBox?

Imatinib: Grade 3 maculopapular lesions and exfoliative reaction: case report by Ammarah Mahmud; Justin W Timbie; Rosalie Malsberger; Claude M Setodji; Amii Kress; Liisa Hiatt; Peter Mendel; Katherine L Kahn is a Economics, Econometrics and Finance article available to read on EtoBox.

What is Imatinib: Grade 3 maculopapular lesions and exfoliative reaction: case report about?

## Objectives: We examined differences in patient outcomes associated with 3 patient-centered medical home (pcmh) recognition programs-national committee for quality assurance (ncqa) level 3, the joint commission (tjc), and accreditation association for ambulatory health care (aaahc)-among medicare beneficiaries receiving care at federally qualified health centers (fqhcs). ## Study design: We used data from cms' fqhc advanced primary care practice demonstration, in which participating fqhcs received assistance to achieve ncqa level 3 pcmh recognition. we assessed the impact of the 3 recognition programs on utilization, quality, and medicare expenditures using a sample of 1108 demonstration and comparison fqhcs. ## Methods: Using propensity-weighted difference-in-differences analyses, we compared changes in outcomes over 3 years for beneficiaries attributed to fqhcs that achieved each type of recognition relative to beneficiaries attributed to fqhcs that did not achieve recognition. ## Results: Recognized fqhcs, compared with nonrecognized fqhcs, were associated with significant 3-year changes in fqhc visits, non-fqhc primary care visits, specialty visits, emergency department (ed)

Who reads Imatinib: Grade 3 maculopapular lesions and exfoliative reaction: case report?

Author

Ammarah Mahmud; Justin W Timbie; Rosalie Malsberger; Claude M Setodji; Amii Kress; Liisa Hiatt; Peter Mendel; Katherine L Kahn

Publisher

Springer Science and Business Media LLC

Published

2018

Language

EN

Field

Economics, Econometrics and Finance (Health Sciences)